Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Management of pilonidal sinus and recurrences in 2025.
J Visc Surg
January 2025
Department of Digestive Surgery, Clinique de La Sauvegarde, avenue Ben-Gourion, 69009 Lyon, France.
Pilonidal sinus is a common pathology of the intergluteal cleft that can develop into abscess or suppuration. This lesion corresponds histologically to a granuloma that organizes around foreign bodies, most often hairs, and fistulizes to the skin through partially epithelialized orifices. If suppuration and abscess develop, treatment is based either on medical treatment combining analgesics, local antiseptics and sometimes antibiotics, or on emergency incision and drainage in the operating room.
View Article and Find Full Text PDFVancomycin-induced acute generalised exanthematous pustulosis.
BMJ Case Rep
January 2025
Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA.
Antibiotics have been well documented to result in several dermatological adverse reactions. Many of these adverse reactions are rashes that are difficult to distinguish. We present a case of a female patient in her 30s with acute generalised exanthematous pustulosis following vancomycin treatment for left breast cellulitis.
View Article and Find Full Text PDFPolymicrobial empyema in a patient with lung adenocarcinomacontaining .
BMJ Case Rep
January 2025
Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania, USA.
A man in his 60s with advanced COPD and lung adenocarcinoma presented with sepsis and acute hypoxaemic respiratory failure. Imaging revealed bilateral pleural effusions, and he was found to have a polymicrobial empyema which included Despite appropriate treatment, he continued to deteriorate and ultimately died of sepsis. species, typically benign constituents of the oral microbiota, rarely can instigate pleuropulmonary infections, especially in immunocompromised individuals.
View Article and Find Full Text PDFA year in review: new treatments and expanded indications in dermatology in 2024.
J Dermatolog Treat
December 2025
Center for Translational Dermatology, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Methods: A literature search was conducted on Drugs@FDA: FDA-Approved Drugs for the year 2024 to identify new dermatologic treatments.
Results: In 2024, the FDA approved seven new dermatologic therapies and expanded the indications for seven current therapies. These therapies treat conditions such as atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, molluscum contagiosum, and alopecia areata, among others.
Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review.
Autoimmun Rev
January 2025
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:
Tuberculosis (TB), caused by Mycobacterium TB, is the most significant infectious cause of mortality across the globe. While TB disease can prey on immunocompetent individuals, it is more likely to occur in immunocompromised individuals. Immune-mediated inflammatory diseases (IMIDs) are a group of diseases (rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, psoriasis, hidradenitis suppurative, autoimmune blistering diseases, and others) where there may be a need for systemic immunosuppression to control the disease manifestations, treat symptoms and improve long term outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!